DAWS affects up to 19% of PD patients who undergo a dopamine agonist taper. ICD is a significant risk factor, not a requirement for development of DAWS. Recent data suggest that history of DBS may also be a risk factor for DAWS. Close surveillance for DAWS is crucial during dopamine agonist taper.